Find Paid Research Studies in Canton, Ohio

Browse Locations ... United States» ... Ohio» ... Canton

Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

Conditions: Asthma; Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: Albuterol Spiromax®
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Not yet recruiting - verified May 2013
Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: GFF MDI (PT003); Drug: GP MDI (PT001); Drug: FF MDI (PT005); Drug: Placebo
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013
Ohio Colorectal Cancer Prevention Initiative

Conditions: Lynch Syndrome; Colorectal Cancer
Interventions: Genetic: LS tumor screening; Genetic: Genetic testing; Behavioral: Genetic Counseling; Other: Biorepository; Behavioral: Questionnaire
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center
Recruiting - verified May 2013
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

Condition: Unresectable Pleural or Peritoneal Malignant Mesothelioma
Interventions: Drug: Tremelimumab; Drug: Placebo
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2013
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)

Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib; Drug: Bortezomib; Drug: Melphalan; Drug: Prednisone
Sponsors: Onyx Pharmaceuticals; Onyx Therapeutics, Inc.
Recruiting - verified May 2013
Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)

Condition: Allergic Rhinitis
Interventions: Drug: BDP Nasal Aerosol; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013
LDL-C Assessment w/ PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Other: Ezetimibe; Other: Placebo (administered subcutaneously); Other: Placebo (administered orally); Drug: Statin therapy
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Condition: Alzheimer's Disease
Interventions: Drug: AC-1204; Drug: Placebo
Sponsors: Accera, Inc.; Accera, Inc.
Recruiting - verified May 2013
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Condition: Alzheimer's Disease
Interventions: Drug: MK-8931; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Conditions: Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event
Interventions: Drug: Dapagliflozin 10 mg; Drug: Placebo tablet
Sponsors: AstraZeneca; AstraZeneca; Bristol-Myers Squibb; The TIMI Study Group; Hadassah Medical Organization
Recruiting - verified May 2013
Video Impact on Neulasta Education

Condition: Breast Cancer
Interventions: Other: Educational DVD 1; Other: Educational DVD 2
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)

Conditions: Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Nonseasonal
Interventions: Biological: MK-8237 tablets; Biological: Placebo tablets; Drug: Rescue Medication: Self-Injectable Epinephrine; Drug: Rescue Medication: Loratadine tablets; Drug: Rescue Medication: Olopatadine ophthalmic drops; Drug: Rescue Medication: Mometasone furoate nasal spray
Sponsors: Merck; Merck
Recruiting - verified May 2013
A Study of Evacetrapib in High-Risk Vascular Disease

Condition: Cardiovascular Diseases
Interventions: Drug: Evacetrapib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; The Cleveland Clinic
Recruiting - verified May 2013
Afatinib Expanded Access Program

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2013
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Condition: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: Drug: fingolimod; Drug: copaxone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Condition: Polycythemia Vera
Interventions: Drug: ruxolitinib and HU-placebo; Drug: HU and ruxolitinib-placebo
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Custirsen + Docetaxel; Drug: Docetaxel
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013
Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011 AM2)

Condition: Asthma
Interventions: Drug: MK-1029; Drug: placebo; Drug: montelukast (ML)
Sponsors: Merck; Merck
Recruiting - verified May 2013
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: nab-paclitaxel; Drug: gemcitabine; Drug: placebo; Drug: M402
Sponsors: Momenta Pharmaceuticals, Inc.; Momenta Pharmaceuticals, Inc.
Recruiting - verified May 2013
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Condition: Asthma
Interventions: Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4; Other: Placebo DPI; Drug: Flovent Diskus 250 mcg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714 AM2)

Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: Dinaciclib; Drug: Ofatumumab
Sponsors: Merck; Merck
Recruiting - verified May 2013
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib plus dexamethasone; Drug: Velcade plus dexamethasone
Sponsors: Onyx Pharmaceuticals; Onyx Pharmaceuticals
Recruiting - verified May 2013
A Dose-ranging Study of Fluticasone Furoate (FF)

Condition: Asthma
Interventions: Drug: Fluticasone Furoate; Drug: Fluticasone Propionate; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PPM3 175 mg eq.; Drug: PPM3 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid emulsion)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.; Drug: PP3M 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid); Drug: PP1M 50 mg eq.; Drug: PP1M 75 mg eq.; Drug: PP1M 100 mg eq.; Drug: PP1M 150 mg eq.
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

Condition: Asthma
Interventions: Drug: Placebo; Drug: Flovent Diskus; Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; PPD
Recruiting - verified April 2013
A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3)

Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug: Mometasone Furoate MDI 100 mcg; Drug: Mometasone Furoate MDI 200 mcg; Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug: Prednisone/prednisolone
Sponsors: Merck; Merck
Recruiting - verified May 2013
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment

Condition: Depression Disorder, Major
Interventions: Drug: RO4995819; Drug: RO4995819; Drug: RO4995819; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

Condition: Epilepsy, Partial Seizures
Intervention: Drug: Pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Condition: Small Cell Lung Carcinoma
Interventions: Biological: Ipilimumab; Biological: Placebo matching Ipilimumab; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma

Condition: Asthma
Interventions: Drug: Placebo; Drug: Albuterol Spiromax®
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified May 2013
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression

Condition: Depression, Bipolar
Interventions: Drug: Placebo; Drug: Cariprazine; Drug: Cariprazine; Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified April 2013
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis

Conditions: Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified May 2013
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V; Biological: PROSTVAC-F; Drug: GM-CSF; Other: GM-CSF Placebo; Biological: Placebo
Sponsors: BN ImmunoTherapeutics; BN ImmunoTherapeutics
Recruiting - verified February 2013
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

Conditions: Diffuse Large B-cell Lymphoma; de Novo DLBCL; DLBCL Transformed From Indolent Lymphoma; Follicular Grade 3 Lymphoma
Interventions: Drug: Pixantrone + Rituximab; Drug: Gemcitabine + Rituximab
Sponsors: Cell Therapeutics; Cell Therapeutics
Recruiting - verified April 2013
Smoking Cessation Study In Healthy Adolescent Smokers

Condition: Smoking Cessation
Interventions: Drug: Varenicline 1mg BID; Drug: Varenicline 0.5mg BID; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

Condition: Warfarin Therapy
Intervention: Device: Warfarin GenoSTAT Test
Sponsors: Iverson Genetic Diagnostics, Inc.; Iverson Genetic Diagnostics, Inc.
Recruiting - verified May 2013
INcrease Of VAgal TonE in CHF

Conditions: Left Ventricular Dysfunction; Heart Failure
Interventions: Device: CardioFit® System; Other: Standard of Care
Sponsors: BioControl Medical; BioControl Medical
Recruiting - verified May 2013
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Imprime PGG + cetuximab; Drug: Cetuximab
Sponsors: Biothera; Biothera
Recruiting - verified May 2013
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Conditions: Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: docetaxel; Drug: cyclophosphamide; Biological: trastuzumab; Drug: paclitaxel; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery

Conditions: Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b; Other: pharmacological study; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013
Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer

Conditions: Dysphagia; Lung Cancer; Pain
Interventions: Drug: Manuka honey; Drug: chemotherapy; Other: questionnaire administration; Procedure: adjuvant therapy; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Procedure: standard follow-up care; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2013
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM3)

Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder {P06107 Has an Extension (P05898; NCT01349907)}(P06107 AM4)

Condition: Bipolar Disorder, Pediatric
Interventions: Drug: asenapine; Drug: Placebo to match asenapine; Drug: Rescue medication
Sponsors: Merck; Merck
Recruiting - verified May 2013
A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome

Condition: Fibromyalgia
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

Condition: Lymphoma, Follicular
Interventions: Biological: Ofatumumab; Biological: Rituximab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Condition: Relapsed/Refractory Multiple Myeloma
Interventions: Drug: plitidepsin + dexamethasone; Drug: dexamethasone
Sponsors: PharmaMar; PharmaMar
Recruiting - verified March 2013
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID; Drug: Enalapril 10 mg BID
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

Conditions: Breast Cancer; Cardiac Toxicity
Interventions: Drug: Coreg CR®; Drug: lisinopril; Other: placebo
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified January 2013
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Conditions: Distal Urethral Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Prostate Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Transitional Cell Carcinoma of the Bladder; Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: cisplatin; Other: placebo; Biological: bevacizumab; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia

Condition: Severe Thrombocytopenia
Intervention: Drug: oprelvekin
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Study of NNZ-2566 in Patients With Traumatic Brain Injury

Condition: Brain Injuries
Intervention: Drug: NNZ-2566
Sponsors: Neuren Pharmaceuticals Limited; Neuren Pharmaceuticals Limited
Recruiting - verified May 2013
The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

Condition: Meningococcal Disease
Intervention: Biological: Meningococcal vaccine GSK134612
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

Conditions: Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: melphalan; Drug: prednisone; Drug: thalidomide; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Conditions: Neoplasms, Breast; Breast Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline; North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; NCIC Clinical Trials Group
Recruiting - verified May 2013
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer

Conditions: Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer
Interventions: Biological: ziv-aflibercept; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Study Evaluating CMC-544 Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Condition: Lymphoma, B-Cell
Interventions: Drug: inotuzumab ozogamicin; Drug: inotuzumab ozogamicin; Drug: inotuzumab ozogamicin
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2013
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer

Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer
Interventions: Drug: cisplatin; Drug: tirapazamine
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI); NCIC Clinical Trials Group
Recruiting - verified May 2013
Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: paclitaxel poliglumex; Other: clinical observation
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI); CTI
Recruiting - verified May 2013

Find Paid Research Studies in Canton, Ohio

Welcome to Paid Research Studies.